Gastric ulcer healing with tripotassium dicitrato bismuthate and subsequent relapse.

Abstract
Fifty patients with endoscopically proven gastric ulcers completed a 1-mo. double-blind randomized trial of tripotassium dicitrato bismuthate (TDB) (DeNol) compared with an identical placebo. Ulcer healing occurred in 18 (72%) of the 25 patients given TDB and in 9 (36%) of the patients given the placebo. The TDB group experienced significantly less pain than the placebo group. During a follow-up of 29 patients with healed ulcers for up to 44 mo., relapse occurred in 13 (45%). It was highest in the first 3 mo. (27%) and had risen to 41% at 2 yr.